306 related articles for article (PubMed ID: 33489922)
1. The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.
Feng Y; Chen X; Cassady K; Zou Z; Yang S; Wang Z; Zhang X
Front Oncol; 2020; 10():611690. PubMed ID: 33489922
[TBL] [Abstract][Full Text] [Related]
2. Utility of mTOR inhibition in hematologic malignancies.
Younes A; Samad N
Oncologist; 2011; 16(6):730-41. PubMed ID: 21632450
[TBL] [Abstract][Full Text] [Related]
3. [m-TOR inhibitors: biology and use in the treatment of haematological diseases].
Balsat M; Cornillon J
Bull Cancer; 2011 Aug; 98(8):935-43. PubMed ID: 21827982
[TBL] [Abstract][Full Text] [Related]
4. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B; Ribrag V
Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
[TBL] [Abstract][Full Text] [Related]
5. Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro.
Trendowski M; Christen TD; Andonova AA; Narampanawe B; Thibaud A; Kusang T; Fondy TP
Invest New Drugs; 2015 Dec; 33(6):1162-74. PubMed ID: 26490657
[TBL] [Abstract][Full Text] [Related]
6. m-TOR inhibitors and their potential role in haematological malignancies.
Calimeri T; Ferreri AJM
Br J Haematol; 2017 Jun; 177(5):684-702. PubMed ID: 28146265
[TBL] [Abstract][Full Text] [Related]
7. Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.
Mohindra NA; Platanias LC
Leuk Lymphoma; 2015; 56(9):2518-23. PubMed ID: 25747970
[TBL] [Abstract][Full Text] [Related]
8. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations.
Magaway C; Kim E; Jacinto E
Cells; 2019 Dec; 8(12):. PubMed ID: 31817676
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
10. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.
Khokhar NZ; Altman JK; Platanias LC
Curr Opin Oncol; 2011 Nov; 23(6):578-86. PubMed ID: 21892085
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.
Chapuis N; Tamburini J; Green AS; Willems L; Bardet V; Park S; Lacombe C; Mayeux P; Bouscary D
Leukemia; 2010 Oct; 24(10):1686-99. PubMed ID: 20703258
[TBL] [Abstract][Full Text] [Related]
12. Cellular immunotherapy for refractory hematological malignancies.
Reagan JL; Fast LD; Safran H; Nevola M; Winer ES; Castillo JJ; Butera JN; Quesenberry MI; Young CT; Quesenberry PJ
J Transl Med; 2013 Jun; 11():150. PubMed ID: 23782682
[TBL] [Abstract][Full Text] [Related]
13. Current phase II clinical data for ridaforolimus in cancer.
Spreafico A; Mackay HJ
Expert Opin Investig Drugs; 2013 Nov; 22(11):1485-93. PubMed ID: 23964772
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Xu RH; Pelicano H; Zhang H; Giles FJ; Keating MJ; Huang P
Leukemia; 2005 Dec; 19(12):2153-8. PubMed ID: 16193082
[TBL] [Abstract][Full Text] [Related]
15. New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.
Waldner M; Fantus D; Solari M; Thomson AW
Br J Clin Pharmacol; 2016 Nov; 82(5):1158-1170. PubMed ID: 26810941
[TBL] [Abstract][Full Text] [Related]
16. Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics.
Alqurashi N; Hashimi SM; Wei MQ
Int J Mol Sci; 2013 Feb; 14(2):3874-900. PubMed ID: 23434669
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
Tasian SK; Teachey DT; Rheingold SR
Front Oncol; 2014; 4():108. PubMed ID: 24904824
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Target of rapamycin signaling in leukemia and lymphoma.
Vu C; Fruman DA
Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.
Witzig TE; Kaufmann SH
Curr Treat Options Oncol; 2006 Jul; 7(4):285-94. PubMed ID: 16916489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
